Valuation: Novacyt

Market Cap 32.63M 37.11M 30.37M 27.89M 52.37M 3.56B 53.06M 361M 141M 1.76B 139M 136M 6.07B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 34.58M 39.34M 32.19M 29.56M 55.51M 3.77B 56.25M 383M 149M 1.86B 148M 144M 6.44B EV / Sales 2026 *
1.13x
EV / Sales 2027 * 1.07x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-2.22%
1 week-1.79%
Current month+11.53%
1 month+13.99%
3 months+23.94%
6 months+5.01%
Current year+12.53%
1 week 0.43
Extreme 0.4315
0.46
1 month 0.38
Extreme 0.3805
0.48
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
3/30/26 Buy

Chief Executive Officer

15,149 0.0214%
3/30/26 Buy

Chairman

1,802 0.0026%
3/30/26 Buy

Chief Executive Officer

56,438 0.0799%
Change 5-day change 1-year change 3-year change Capi.($)
-2.22%-1.79%-5.68%-38.55% 37.11M
+1.43%-1.62%-37.08%-43.95% 635M
-3.17%-30.46%+169.74% - 460M
-0.91%-2.15%-40.00%+5.54% 109M
+3.11%+2.32%+12.77%+66.67% 98.19M
Average -0.35%-5.25%+19.95%-2.57% 267.85M
Weighted average by Cap. -0.32%-8.08%+38.29%-25.22%

Financials

2026 *2027 *
Net sales 30.52M 34.72M 28.41M 26.1M 49M 3.33B 49.65M 338M 132M 1.64B 130M 128M 5.68B 34.86M 39.66M 32.45M 29.8M 55.96M 3.8B 56.7M 386M 151M 1.88B 149M 146M 6.49B
Net income - -
Net Debt 1.96M 2.23M 1.82M 1.67M 3.14M 213M 3.18M 21.64M 8.45M 105M 8.35M 8.17M 364M 4.84M 5.51M 4.51M 4.14M 7.77M 528M 7.88M 53.58M 20.92M 261M 20.68M 20.23M 901M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-07-28 0.4400 -2.22% 69,507
26-07-27 €0.4500 +0.90% 30,108
26-07-24 €0.4460 -0.45% 74,851
26-07-23 €0.4480 -0.22% 174,628
26-07-22 €0.4490 +0.22% 52,420

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock